Home World News Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line... World News Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC By Ogkologos - August 11, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMMIT study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Today is Giving Tuesday December 1, 2020 Low Dose Dexamethasone Effective as Premedication for Taxanes to Prevent Hypersensitivity... August 10, 2021 PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... October 11, 2022 Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable... August 28, 2025 Load more HOT NEWS Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Courageous children receive Star Awards in virtual celebration EMA Recommends Granting a Marketing Authorisation for Sugemalimab Data from a Large Cohort of Patients with mRCC Demonstrate the...
